Ilyang Pharmaceutical "COVID-19 Treatment Fails to Prove Efficacy in Russian Phase 3 Clinical Trial"

[Asia Economy Reporter Ji Yeon-jin] Ilyang Pharmaceutical announced on the 4th that it conducted a Phase 3 clinical trial with Russian R-Pharm for the treatment of COVID-19 using Radotinib, which is used as a treatment for chronic myeloid leukemia, but failed to demonstrate superior efficacy compared to the standard recommended treatment.

Russian R-Pharm will not apply for marketing approval of Radotinib for the treatment of COVID-19 patients in Russia and plans to complete the registration of Radotinib for the indication of chronic myeloid leukemia within this year.